New hope for Hard-to-Treat colorectal cancer: targeted combo trial launches

NCT ID NCT06838338

Ongoing Disease control Sponsor: Jian Li Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called JAB-21822, which targets a specific genetic mutation (KRAS G12C), combined with standard chemotherapy and bevacizumab. The study includes 30 Chinese patients with advanced colorectal cancer that has not responded to first-line treatment. The goal is to see if this combination can shrink tumors and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JAB-21822 (a KRAS G12C inhibitor) combined with standard second-line chemotherapy (FOLFIRI or FOLFOX) and bevacizumab
What this could lead to: If successful, this could offer a new treatment option for Chinese patients with KRAS G12C colorectal cancer who have run out of standard options.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. The combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, China
Fudan University Shanghai Cancer Center

Shanghai, China
Peking University Cancer Hospital (Inner Mongolia Campus)/Afffliated Cancer Hospital of Inner Mongolia Medical University

Hohhot, China
Peking University First Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.